Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com
SOURCE Infinity Pharmaceuticals, Inc.
- David Beier Appointed to Board of Directors -
- Leadership Team Expanded with Addition of VP Clinical Development Dr. Marie-Louise Fjällskog and Promotion of Dr. Suresh Mahabhashyam -
- Scientific Advisory Board Established with Thought Leaders in Immuno-Oncology -
CAMBRIDGE, Mass., March 8, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that it has added to its Board of Directors, expanded its clinical leadership team, and established a Scientific Advisory Board.
"We are pleased to announce the appointment of David Beier, J.D. to our Board of Directors," said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. "David's deep insights on healthcare policy, economics and drug pricing, together with his perspectives as an advisor to the Parker Institute for Cancer Immunotherapy, will be invaluable as we advance IPI-549, a potentially first-in-class immuno-oncology medicine."
"We are also thrilled to have Dr. Marie-Louise Fjällskog, join the exceptional clinical team at Infinity and to recognize the contributions of Dr. Suresh Mahabhashyam, in the development of IPI-549," Ms. Perkins continued. "In addition, we are delighted to announce the establishment of a Scientific Advisory Board with key immuno-oncology thought leaders, including Dmitry Gabrilovich, M.D., Ph.D., Roy Herbst, M.D., Ph.D., Stephen Hodi, M.D., and David Munn, M.D. The depth of their collective clinical oncology experience, especially in the rapidly-evolving field of immuno-oncology, will be critical as we generate important data on IPI-549 this year and determine the optimal path forward for this first-in-class product candidate."
David Beier, J.D., is a Managing Director of Bay City Capital and brings a wealth of experience to the Infinity Board. David serves as an advisor to the Parker Institute for Cancer Immunotherapy, a Senior Fellow at the USC Schaeffer Center for Health Policy & Economics and as a member of the Board of Directors of Arcus Biosciences, UCSF Benioff Children's Hospitals and the California Life Sciences Association. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. Having spent two decades as part of the senior management teams for Amgen and Genentech, he brings invaluable perspective regarding strategy for entrepreneurial biotechnology firms and the industry in general as a globally recognized leader in health care policy, regulatory affairs, healthcare economics, and pricing. Mr. Beier also previously served in the White House during the Clinton Administration as a Chief Domestic Policy Advisor to the Vice President.
"Infinity has a tremendous team, including top-tier investigators, advisors, board, and management," said Mr. Beier. "I look forward to working with them to optimize the value of IPI-549 for patients and shareholders, based on important data being generated on IPI-549 this year."
Marie-Louise Fjällskog M.D., Ph.D., has been appointed as Vice President of Clinical Development and will play an integral role in the expanded clinical development of IPI-549. Dr. Fjällskog is an Associate Professor of Oncology at Uppsala University, Sweden, and has over twenty-five years of experience in clinical oncology, translational research, and drug development. She joins Infinity from the Novartis Institute for Biomedical Research, where she served as a Clinical Program Leader, Translational Clinical Oncology, and as the global lead for several immuno-oncology programs, including those targeting CSF-1 and PD-1.
In addition, Suresh Mahabhashyam, M.D., M.P.H., has been promoted to Vice President, Safety and Risk Management. Dr. Mahabhashyam has over 20 years of experience in medical practice and epidemiology with the last decade focused on drug development at Infinity, Alexion and Allergan.
"Infinity has a significant opportunity with IPI-549, which represents a novel approach within immuno-oncology and is the only selective PI3K-gamma inhibitor in clinical development. I am excited to join the company at this time and to work with the team to bring this potentially transformative treatment through clinical development, and to patients," said Dr. Fjällskog.
Infinity has also established a Scientific Advisory Board of thought leaders in the field of immuno-oncology to complement the expertise of its clinical investigators. Their collective input will be invaluable in analyzing the breadth of IPI-549 clinical and translational data being generated this year. Infinity's Scientific Advisory Board's initial members include:
Infinity is an innovative biopharmaceutical company dedicated to advancing novel cancer treatments. Infinity is advancing IPI-549, a potentially transformative immuno-oncology approach that aims to reprogram tumor-associated macrophages by selectively inhibiting PI3K-gamma. A Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of PI3K-gamma selective inhibition and IPI-549, clinical trial plans regarding IPI-549, and the company's ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. These factors, risks and uncertainties include: Infinity's results of clinical trials and preclinical studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; Infinity's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of agents by Infinity's competitors for diseases in which Infinity is currently developing or intends to develop IPI-549; Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for IPI-549; and those risks and uncertainties described in greater detail under the caption "Risk Factors" included in Infinity's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 7, 2017, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Stephanie Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com
View original content:http://www.prnewswire.com/news-releases/infinity-pharmaceuticals-announces-additions-to-board-of-directors-and-clinical-leadership-team-and-establishes-scientific-advisory-board-300610459.html
©2017 PR Newswire. All Rights Reserved.